Google Scholar: cites
Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection
Stalin Raj, V. (Erasmus Medical Center. Department of Viroscience)
Okba, Nisreen M. A. (Erasmus Medical Center. Department of Viroscience)
Gutierrez-Alvarez, Javier (National Center for Biotechnology. Department of Molecular and Cell Biology)
Drabek, Dubravka (Department of Cell Biology. Erasmus Medical Center)
van Dieren, Brenda (Utrecht University. Department of Infectious Diseases and Immunology)
Widagdo, W. (Erasmus Medical Center. Department of Viroscience)
Lamers, Mart M. (Erasmus Medical Center. Department of Viroscience)
Widjaja, Ivy (Utrecht University. Department of Infectious Diseases and Immunology)
Fernandez-Delgado, Raul (National Center for Biotechnology. Department of Molecular and Cell Biology)
Sola, Isabel (National Center for Biotechnology. Department of Molecular and Cell Biology)
Bensaid, Albert (Institut de Recerca i Tecnologia Agroalimentàries. Centre de Recerca en Sanitat Animal)
Koopmans, Marion P.G (Erasmus Medical Center. Department of Viroscience)
Segalés Coma, Joaquim (Universitat Autònoma de Barcelona. Departament de Sanitat i d'Anatomia Animals)
Osterhaus, Albert D. M. E. (University of Veterinary Medicine. Center for Infection Medicine and Zoonoses Research)
Bosch, Berend-Jan (Utrecht University. Department of Infectious Diseases and Immunology)
Enjuanes, Luis (National Center for Biotechnology. Department of Molecular and Cell Biology)
Haagmans, Bart L. (Erasmus Medical Center. Department of Viroscience)

Data: 2018
Resum: Dromedary camel heavy chain-only antibodies may provide novel intervention strategies against MERS coronavirus. Middle East respiratory syndrome coronavirus (MERS-CoV) continues to cause outbreaks in humans as a result of spillover events from dromedaries. In contrast to humans, MERS-CoV-exposed dromedaries develop only very mild infections and exceptionally potent virus-neutralizing antibody responses. These strong antibody responses may be caused by affinity maturation as a result of repeated exposure to the virus or by the fact that dromedaries-apart from conventional antibodies-have relatively unique, heavy chain-only antibodies (HCAbs). These HCAbs are devoid of light chains and have long complementarity-determining regions with unique epitope binding properties, allowing them to recognize and bind with high affinity to epitopes not recognized by conventional antibodies. Through direct cloning and expression of the variable heavy chains (VHHs) of HCAbs from the bone marrow of MERS-CoV-infected dromedaries, we identified several MERS-CoV-specific VHHs or nanobodies. In vitro, these VHHs efficiently blocked virus entry at picomolar concentrations. The selected VHHs bind with exceptionally high affinity to the receptor binding domain of the viral spike protein. Furthermore, camel/human chimeric HCAbs-composed of the camel VHH linked to a human Fc domain lacking the CH1 exon-had an extended half-life in the serum and protected mice against a lethal MERS-CoV challenge. HCAbs represent a promising alternative strategy to develop novel interventions not only for MERS-CoV but also for other emerging pathogens.
Ajuts: European Commission. Horizon 2020 653316
Ministerio de Ciencia e Innovación Bio2016-75549-R
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: Article ; recerca ; Versió publicada
Publicat a: Science advances, Vol. 4 (august 2018) , ISSN 2375-2548

DOI: 10.1126/sciadv.aas9667
PMID: 30101189


10 p, 1.1 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Centre de Recerca en Sanitat Animal (CReSA-IRTA)
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2022-02-07, darrera modificació el 2022-12-16



   Favorit i Compartir